Dr. Minniti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
174 Democrat Rd
Mickleton, NJ 08056Phone+1 856-423-0754Fax+1 856-423-7508
Education & Training
- Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
- Fox Chase Cancer CenterFellowship, Medical Oncology, 1989 - 1992
- Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1986 - 1989
- Ponce Health Sciences University School of MedicineClass of 1986
- Saint Joseph's UniversityBS, Biology, 1978 - 1982
Certifications & Licensure
- NJ State Medical License 1988 - 2025
- PA State Medical License 1989 - 2024
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- David King Community Clinical Scientist National Award ACCC Association of Community Cancer Centers, 2010
- Physician of the Year New Jersey Hospice & Palliative Care Organization, 2012
- Service to Mankind Award The Leukemia & Lymphoma Society Southern New Jersey Chapter, 2001
- Join now to see all
Clinical Trials
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Start of enrollment: 2023 Jul 13
Roles: Principal Investigator
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Start of enrollment: 2022 Aug 01
- Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
- Join now to see all
Publications & Presentations
PubMed
- 60 citationsDrosophila Muller F Elements Maintain a Distinct Set of Genomic Properties Over 40 Million Years of EvolutionWilson Leung, Christopher D. Shaffer, Laura K. Reed, Sheryl T. Smith, William D. Barshop
G3. 2015-05-01 - 10 citationsVinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.Naomi B. Haas, Bruce J. Giantonio, Samuel Litwin, C. Minniti, Stephen Fox
Cancer. 2003-11-01 - 3 citationsPhase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSFP.A. Ford, S.G. Arbuck, C. Minniti, L.L. Miller, D. Demaria
European Journal of Cancer. 1996-04-01
Journal Articles
- Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Group study (E5493)Wiernik PH, Li H, Weller E, Hochster HS, Horning SJ, Nazeer T, Gordon L, Haberman T, Minniti CJ Jr, Shapiro GR, Cassileth PA, Leukemia & Lymphoma, 1/1/2012
- Phase III toxicity trial of carboplatin (Cb) plus either Docetaxel (D) or paclitaxel (P) in advanced non-small cell lung cancer (NSCLC): Final results of OPN 001Langer CJ, Babb J, Minniti C, et al, Lung Cancer, 1/1/2003
- Vinblastine and estramustine phosphate in metastatic renal cell carcinoma; A phase II trial of the Fox Chase NetworkHaas N, Giantonio BJ, Litwin S, Minniti Jr CJ, Fox S, Yeslow G, Reilly R, Nahum K, Greenberg R, Halbherr T, Hudes GR, CA: A Cancer Journal for Clinicians, 1/1/2003
- Join now to see all
Books/Book Chapters
Committees
- Chair, Cancer Committee Inspira Medical Center Mullica Hill 1998 - Present
- Chair, Tumor Board Inspira Medical Center Mullica Hill 1997 - Present
Professional Memberships
- Fellow
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: